Organization (Other)
Intergroupe Francophone de Cancérologie Thoracique
ClinicalTrials.gov lists Intergroupe Francophone de Cancérologie Thoracique as lead sponsor of 57 trials. It has 90 active development programs and 28 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 4 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Intergroupe Francophone de Cancérologie Thoracique: 57 lead-sponsored trials and 1 legal-entity registration.
Disease areas (15)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lung Neoplasms | 48 |
| Carcinoma, Non-Small-Cell Lung | 35 |
| Mesothelioma | 5 |
| Small Cell Lung Carcinoma | 5 |
| Adenocarcinoma of Lung | 2 |
Showing 5 of 15 disease areas.
Trials by start year as sponsor or collaborator (25)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 3 |
| 2024 | 1 |
| 2023 | 2 |
| 2022 | 4 |
| 2021 | 5 |
| 2020 | 4 |
| 2019 | 4 |
| 2018 | 1 |
| 2017 | 3 |
Showing 10 of 25 years.
Prediction, not a registry value: median 36 months or more (the model's horizon) from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; 7 of 7 predicted trials reach the 36-month horizon; registered median of 37 months across 44 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (90)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| PEMETREXED | Lung Neoplasms | Phase 3 | 7 |
| PEMETREXED | Carcinoma, Non-Small-Cell Lung | Phase 3 | 6 |
| (nab)-paclitaxel | Lung Neoplasms | Phase 3 | 4 |
| (nab)-paclitaxel | Carcinoma, Non-Small-Cell Lung | Phase 3 | 3 |
| ATEZOLIZUMAB | Lung Neoplasms | Phase 3 | 4 |
Showing 5 of 90 active programs.
Approved assets (28)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| PEMETREXED | 8 |
| CARBOPLATIN | 6 |
| (nab)-paclitaxel | 6 |
| NIVOLUMAB | 5 |
| ATEZOLIZUMAB | 5 |
Showing 5 of 28 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 48% hit target (n=21) | 30% on time (n=23) |
Journals published in (34)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Lung cancer (Amsterdam, Netherlands) | 12 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 9 |
| European journal of cancer (Oxford, England : 1990) | 8 |
| Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 8 |
| The Lancet. Oncology | 8 |
Showing 5 of 34 journals.
Organization relationships (24)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Groupe Français de Pneumo-Cancérologie | Co sponsors trial with | 3 |
| National Cancer Institute, Naples | Co sponsors trial with | 2 |
| Canadian Cancer Trials Group | Co sponsors trial with | 2 |
| Fédération Francophone de Cancérologie Digestive | Co sponsors trial with | 1 |
| The Christie NHS Foundation Trust | Co sponsors trial with | 1 |
Showing 5 of 24 relationships.
Latest dated events (65)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 65 events.
Biomarker capability evidence (287)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALK | Trial sponsor | Named in trial inclusion criteria |
| ALK | Trial sponsor | Named in trial inclusion criteria |
| ALK | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 287 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.